NASDAQ:GWPH - GW Pharmaceuticals PLC- Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$121.1950 +0.33 (+0.27 %)
(As of 12/14/2018 10:16 AM ET)
Previous Close$120.86
Today's Range$119.50 - $121.1950
52-Week Range$105.12 - $179.65
Volume36,276 shs
Average Volume395,298 shs
Market Capitalization$3.78 billion
P/E Ratio-11.48
Dividend YieldN/A
Beta2.16
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia. Further, the company has license and development agreements with Otsuka Pharmaceutical Co. Ltd.; Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GWPH
Previous Symbol
CUSIPN/A
Phone44-12-2326-6800

Debt

Debt-to-Equity Ratio0.01
Current Ratio6.66
Quick Ratio6.34

Price-To-Earnings

Trailing P/E Ratio-11.48
Forward P/E Ratio-13.12
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.74 million
Price / Sales286.91
Cash FlowN/A
Price / Cash FlowN/A
Book Value$13.76 per share
Price / Book8.81

Profitability

EPS (Most Recent Fiscal Year)($10.56)
Net Income$-295,160,000.00
Net Margins-1,574.21%
Return on Equity-50.93%
Return on Assets-44.64%

Miscellaneous

Employees769
Outstanding Shares30,160,000
Market Cap$3.78 billion
OptionableOptionable

GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions

What is GW Pharmaceuticals PLC-'s stock symbol?

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

How were GW Pharmaceuticals PLC-'s earnings last quarter?

GW Pharmaceuticals PLC- (NASDAQ:GWPH) issued its quarterly earnings data on Tuesday, November, 27th. The biopharmaceutical company reported ($2.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.48) by $0.28. The biopharmaceutical company had revenue of $2.40 million for the quarter, compared to analysts' expectations of $2.62 million. GW Pharmaceuticals PLC- had a negative net margin of 1,574.21% and a negative return on equity of 50.93%. The company's revenue for the quarter was down 4.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.14) earnings per share. View GW Pharmaceuticals PLC-'s Earnings History.

When is GW Pharmaceuticals PLC-'s next earnings date?

GW Pharmaceuticals PLC- is scheduled to release their next quarterly earnings announcement on Monday, February 4th 2019. View Earnings Estimates for GW Pharmaceuticals PLC-.

What price target have analysts set for GWPH?

9 Wall Street analysts have issued 1-year price targets for GW Pharmaceuticals PLC-'s shares. Their forecasts range from $142.00 to $227.00. On average, they expect GW Pharmaceuticals PLC-'s share price to reach $183.00 in the next year. This suggests a possible upside of 51.4% from the stock's current price. View Analyst Price Targets for GW Pharmaceuticals PLC-.

What is the consensus analysts' recommendation for GW Pharmaceuticals PLC-?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GW Pharmaceuticals PLC-.

Has GW Pharmaceuticals PLC- been receiving favorable news coverage?

News headlines about GWPH stock have been trending somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. GW Pharmaceuticals PLC- earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.

Who are some of GW Pharmaceuticals PLC-'s key competitors?

Who are GW Pharmaceuticals PLC-'s key executives?

GW Pharmaceuticals PLC-'s management team includes the folowing people:
  • Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Exec. Chairman (Age 64)
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 47)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 48)
  • Mr. Christopher John Tovey BSc, Chief Operating Officer (Age 53)
  • Mr. Douglas B. Snyder, Chief Legal Officer (Age 54)

Who are GW Pharmaceuticals PLC-'s major shareholders?

GW Pharmaceuticals PLC-'s stock is owned by a number of of retail and institutional investors. Top institutional investors include Capital World Investors (8.35%), Scopia Capital Management LP (4.93%), Janus Henderson Group PLC (1.97%), BlackRock Inc. (1.89%), Pictet Asset Management Ltd. (1.65%) and Morgan Stanley (1.43%).

Which institutional investors are selling GW Pharmaceuticals PLC- stock?

GWPH stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Jennison Associates LLC, Deutsche Bank AG, Janus Henderson Group PLC, Renaissance Technologies LLC, BlackRock Inc., Point72 Asset Management L.P. and Victory Capital Management Inc..

Which institutional investors are buying GW Pharmaceuticals PLC- stock?

GWPH stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Capital World Investors, Capital International Investors, Pictet Asset Management Ltd., Baker BROS. Advisors LP, Morgan Stanley, Dorsey Wright & Associates and FMR LLC.

How do I buy shares of GW Pharmaceuticals PLC-?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GW Pharmaceuticals PLC-'s stock price today?

One share of GWPH stock can currently be purchased for approximately $120.86.

How big of a company is GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- has a market capitalization of $3.78 billion and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-295,160,000.00 in net income (profit) each year or ($10.56) on an earnings per share basis. GW Pharmaceuticals PLC- employs 769 workers across the globe.

What is GW Pharmaceuticals PLC-'s official website?

The official website for GW Pharmaceuticals PLC- is http://www.gwpharm.com.

How can I contact GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]


MarketBeat Community Rating for GW Pharmaceuticals PLC- (NASDAQ GWPH)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  506 (Vote Outperform)
Underperform Votes:  262 (Vote Underperform)
Total Votes:  768
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC- and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel